CR20120493A - PARENTERAL PHARMACEUTICAL FORM, WHICH RELEASES INHIBITORS OF AROMATASE AND GESTAGENS FOR THE TREATMENT OF ENDOMETRIOSIS - Google Patents
PARENTERAL PHARMACEUTICAL FORM, WHICH RELEASES INHIBITORS OF AROMATASE AND GESTAGENS FOR THE TREATMENT OF ENDOMETRIOSISInfo
- Publication number
- CR20120493A CR20120493A CR20120493A CR20120493A CR20120493A CR 20120493 A CR20120493 A CR 20120493A CR 20120493 A CR20120493 A CR 20120493A CR 20120493 A CR20120493 A CR 20120493A CR 20120493 A CR20120493 A CR 20120493A
- Authority
- CR
- Costa Rica
- Prior art keywords
- endometriosis
- treatment
- aromatase
- gestagens
- inhibitors
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title abstract 2
- 102000014654 Aromatase Human genes 0.000 title 1
- 108010078554 Aromatase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000583 progesterone congener Substances 0.000 title 1
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 2
- 239000003886 aromatase inhibitor Substances 0.000 abstract 2
- 230000000638 stimulation Effects 0.000 abstract 2
- 102000006771 Gonadotropins Human genes 0.000 abstract 1
- 108010086677 Gonadotropins Proteins 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 230000003325 follicular Effects 0.000 abstract 1
- 239000002622 gonadotropin Substances 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 239000006201 parenteral dosage form Substances 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
El contenido de la presente invención para el tratamiento de endometriosis consiste en proporcionar una forma farmacéutica parenteral (sistema de administración) para la liberación controlada de un inhibidor de aromatasa (AI) con una tasa de liberación diaria, que no induce una estimulación de los ovarios por reacoplamiento negativo del eje hipófisis-ovario (que provocaría una secreción de gonadotropinas y estimulación del crecimiento folicular ovárico),The content of the present invention for the treatment of endometriosis is to provide a parenteral dosage form (administration system) for the controlled release of an aromatase inhibitor (AI) with a daily release rate, which does not induce a stimulation of the ovaries. by negative re-coupling of the pituitary-ovarian axis (which would cause gonadotropin secretion and stimulation of ovarian follicular growth),
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010003494A DE102010003494A1 (en) | 2010-03-31 | 2010-03-31 | Parenteral delivery system that releases aromatase inhibitors and progestins for the treatment of endometriosis |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20120493A true CR20120493A (en) | 2012-11-22 |
Family
ID=44021822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20120493A CR20120493A (en) | 2010-03-31 | 2012-09-27 | PARENTERAL PHARMACEUTICAL FORM, WHICH RELEASES INHIBITORS OF AROMATASE AND GESTAGENS FOR THE TREATMENT OF ENDOMETRIOSIS |
Country Status (41)
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2782584T (en) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
JP2017516768A (en) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | Natural combination hormone replacement therapy and therapy |
MX2017015229A (en) * | 2015-05-27 | 2018-02-19 | Quest Diagnostics Invest Llc | Methods for mass spectrometric quantitation of analytes extracted from a microsampling device. |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
RU2732822C2 (en) * | 2015-12-21 | 2020-09-22 | Байер Ой | Method for preparing a drug delivery device and a drug delivery device made by said method |
KR20180126582A (en) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
GB201614179D0 (en) * | 2016-08-19 | 2016-10-05 | Mereo Biopharma 2 Ltd | Dosage regimen for the treatment of endometriosis |
CN109248166A (en) * | 2017-07-13 | 2019-01-22 | 国家卫生计生委科学技术研究所 | The preparation and application of Anastrozole depot pesseulum |
US10918649B2 (en) | 2019-06-21 | 2021-02-16 | The Population Council, Inc. | System for providing birth control |
US20240122885A1 (en) * | 2021-02-12 | 2024-04-18 | The Regents Of The University Of California | Endometriosis-Related Methods and Compositions |
CN115804762B (en) * | 2022-12-20 | 2024-05-31 | 浙江大学 | Macrophage membrane coated ectopic endometrium targeting nanoparticle, preparation method and application |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8517360D0 (en) * | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
JP2602456B2 (en) * | 1990-04-12 | 1997-04-23 | 雪印乳業株式会社 | Endometriosis treatment |
FI95768C (en) * | 1993-06-17 | 1996-03-25 | Leiras Oy | Intravaginal dosing system |
US7744916B2 (en) * | 1997-06-11 | 2010-06-29 | Umd, Inc. | Coated vaginal device for delivery of anti-migraine and anti-nausea drugs |
FI20000572A (en) * | 2000-03-13 | 2001-09-14 | Leiras Oy | Device intended for application of implants |
EP1377298B1 (en) * | 2001-01-26 | 2006-08-30 | Pfizer Italia S.r.l. | Exemestane for treating hormono-dependent disorders |
GB0120147D0 (en) | 2001-08-17 | 2001-10-10 | Metris Therapeutics Ltd | Treatment method |
WO2003017973A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method |
GB0302572D0 (en) * | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
GB0320238D0 (en) * | 2003-08-29 | 2003-10-01 | Medical Res Council | Treatment of disease |
US20050101579A1 (en) * | 2003-11-06 | 2005-05-12 | Shippen Eugene R. | Endometriosis treatment protocol |
AR066166A1 (en) * | 2007-09-21 | 2009-07-29 | Organon Nv | DRUG SUPPLY SYSTEM |
TW200927141A (en) * | 2007-11-22 | 2009-07-01 | Bayer Schering Pharma Oy | Vaginal delivery system |
US20110033519A1 (en) | 2009-08-07 | 2011-02-10 | Leong Madeline | Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use |
-
2010
- 2010-03-31 DE DE102010003494A patent/DE102010003494A1/en not_active Withdrawn
-
2011
- 2011-03-28 MY MYPI2012004360A patent/MY160353A/en unknown
- 2011-03-28 PT PT11714245T patent/PT2552404E/en unknown
- 2011-03-28 CN CN201180017806.6A patent/CN103002873B/en not_active Expired - Fee Related
- 2011-03-28 MX MX2012011329A patent/MX2012011329A/en active IP Right Grant
- 2011-03-28 US US13/638,243 patent/US20130131027A1/en not_active Abandoned
- 2011-03-28 NZ NZ602698A patent/NZ602698A/en not_active IP Right Cessation
- 2011-03-28 EA EA201201358A patent/EA025582B1/en not_active IP Right Cessation
- 2011-03-28 SI SI201130435T patent/SI2552404T1/en unknown
- 2011-03-28 ES ES11714245.5T patent/ES2533101T3/en active Active
- 2011-03-28 CA CA2794790A patent/CA2794790A1/en not_active Abandoned
- 2011-03-28 PE PE2012001815A patent/PE20130524A1/en not_active Application Discontinuation
- 2011-03-28 BR BR112012024739A patent/BR112012024739A2/en not_active IP Right Cessation
- 2011-03-28 UA UAA201212231A patent/UA109655C2/en unknown
- 2011-03-28 WO PCT/EP2011/054737 patent/WO2011120925A1/en active Application Filing
- 2011-03-28 MA MA35266A patent/MA34099B1/en unknown
- 2011-03-28 DK DK11714245.5T patent/DK2552404T3/en active
- 2011-03-28 JP JP2013501792A patent/JP6012048B2/en not_active Expired - Fee Related
- 2011-03-28 PL PL11714245T patent/PL2552404T3/en unknown
- 2011-03-28 ME MEP-2015-39A patent/ME02159B/en unknown
- 2011-03-28 AU AU2011234587A patent/AU2011234587B2/en not_active Ceased
- 2011-03-28 EP EP11714245.5A patent/EP2552404B1/en active Active
- 2011-03-28 KR KR1020127025671A patent/KR20130010047A/en not_active Application Discontinuation
- 2011-03-28 SG SG2012068847A patent/SG184111A1/en unknown
- 2011-03-28 RS RS20150188A patent/RS53876B1/en unknown
- 2011-03-30 UY UY0001033303A patent/UY33303A/en not_active Application Discontinuation
- 2011-03-30 TW TW100111100A patent/TWI576107B/en not_active IP Right Cessation
- 2011-03-30 AR ARP110101037A patent/AR080861A1/en unknown
- 2011-03-30 TW TW105118443A patent/TW201632184A/en unknown
-
2012
- 2012-09-13 ZA ZA2012/06869A patent/ZA201206869B/en unknown
- 2012-09-23 IL IL222056A patent/IL222056A/en not_active IP Right Cessation
- 2012-09-24 EC ECSP12012176 patent/ECSP12012176A/en unknown
- 2012-09-27 CR CR20120493A patent/CR20120493A/en unknown
- 2012-09-27 TN TNP2012000468A patent/TN2012000468A1/en unknown
- 2012-09-28 CO CO12170798A patent/CO6630125A2/en unknown
- 2012-09-28 DO DO2012000255A patent/DOP2012000255A/en unknown
- 2012-09-28 CL CL2012002722A patent/CL2012002722A1/en unknown
- 2012-09-28 CU CU2012000145A patent/CU20120145A7/en unknown
- 2012-09-28 GT GT201200267A patent/GT201200267A/en unknown
-
2013
- 2013-06-13 HK HK13106968.0A patent/HK1179531A1/en not_active IP Right Cessation
-
2015
- 2015-03-16 HR HRP20150294TT patent/HRP20150294T1/en unknown
- 2015-03-17 CY CY20151100269T patent/CY1116187T1/en unknown
- 2015-06-18 US US14/743,935 patent/US20150359802A1/en not_active Abandoned
-
2016
- 2016-06-09 JP JP2016115248A patent/JP2016164200A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20120493A (en) | PARENTERAL PHARMACEUTICAL FORM, WHICH RELEASES INHIBITORS OF AROMATASE AND GESTAGENS FOR THE TREATMENT OF ENDOMETRIOSIS | |
AR117670A2 (en) | ANDROGEN RECEPTOR MODULATOR AND ITS USES | |
AR127861A2 (en) | PHARMACEUTICAL COMPOSITION INCLUDING PEPTIDE PROTEASOME INHIBITORS AND CYCLODEXTRIN | |
CO7240407A2 (en) | Crystal forms of an androgenic receptor modulator | |
CL2016003295A1 (en) | Intermittent dosing of an mdm2 inhibitor. | |
AR097619A1 (en) | USE OF ACETIL-COA CARBOXYLASE INHIBITORS TO TREAT ACNÉ VULGARIS | |
IN2014DN06529A (en) | ||
PE20142239A1 (en) | INTRAUTERINE SYSTEMS, IUD INSERTION DEVICES, AND RELATED METHODS AND KITS THEREOF | |
BR112016008576A2 (en) | STABLE AQUEOUS FORMULATIONS OF ANTIBODIES AND PHARMACEUTICAL UNIT DOSAGE FORM | |
BR112013004440A2 (en) | method for parenteral administration of a composition, pharmaceutical composition for parenteral administration, kit and pharmaceutical system for parenteral administration | |
AR077225A1 (en) | INJECTABLE FORMULATIONS CONTAINING ASENAPINE AND TREATMENT METHOD THAT USES THEM | |
GT201400059A (en) | DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES | |
EA201400737A1 (en) | DELIVERY SYSTEM ON THE BASIS OF A PELLET SET WITH IMMEDIATE release of an ACTIVE SUBSTANCE | |
PE20150190A1 (en) | PHARMACEUTICAL FORMULATION | |
UY34178A (en) | DOSAGE AND ADMINISTRATION OF ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH PACLITAXEL FOR THE TREATMENT OF GYNECOLOGICAL CANCER. | |
CL2016001094A1 (en) | Microporous zirconium silicate for the treatment of hyperkalemia. | |
MX337464B (en) | Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents. | |
EA201490862A1 (en) | OSMOTICALLY ACTIVE VAGINAL DELIVERY SYSTEM | |
UY34154A (en) | DOSAGE AND ADMINISTRATION OF ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH PACLITAXEL. | |
AR095834A1 (en) | DOSAGE FORM OF A PROGESTERONE RECEIVER ANTAGONIST, PHARMACEUTICAL COMPOSITION | |
UY35004A (en) | STABILIZED AMORFA FORM OF AGOMELATIN, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
UA116104C2 (en) | Inhibitors of the cd95 signaling pathway for treatment of mds | |
AR125339A2 (en) | NOTCH PATH SIGNALING INHIBITOR COMPOUND | |
EA201592232A1 (en) | APPLICATION OF DENTSIKHIN IN OBTAINING A MEDICINE FOR THE TREATMENT OF THROMBOCYTOPIA | |
UA97716U (en) | MEDICINE IN THE FORM OF SYRUP CONTAINING FENSPIRIDE HYDROCHLORIDE |